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SUMMARY –The use of lasers for treatment of oral leukoplakia has gained a lot of interest in the 
past years, however, data on the use of Er:YAG laser are scarce. The aim of this study was to compare 
the efficacy of Er:YAG laser and 1% topical isotretinoin in the treatment of 27 oral leukoplakia pa-
tients. Er:YAG laser (LightWalker AT, Fotona, Slovenia) was used in 27 patients with 27 leukoplakia 
lesions. Postoperative pain was assessed by use of visual analog scale (VAS), and the impact of laser 
treatment on the quality of life was assessed by the OHIP-14 questionnaire (Croatian version). Con-
trol group consisted of the same 27 patients previously treated with 1% topical isotretionin three times 
a day during the period of one year. No improvement in the size of leukoplakia lesions was observed 
after treatment with topical isotretinoin. There were significant differences between men and women 
according to leukoplakia localization, number of laser sessions and VAS (p<0.05). At follow-up after 
six months and one year, there was no recurrence of lesions. Er:YAG laser is a successful treatment for 
oral leukoplakia. Topical isotretionin treatment is unsuccessful in patients with oral leukoplakia.
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Introduction
Leukoplakia is a clinical term used to describe a 
white plaque on the oral mucosa that cannot be re-
moved by scraping and which has an unknown etiol-
ogy except for cases of tobacco use1,2. Various treat-
ments have been suggested for the treatment of oral 
leukoplakia; however, the rate of its recurrence is still 
high3. Surgical treatment options for leukoplakic le-
sions may include scalpel excision, electrocoagulation, 
cryotherapy and laser therapy (CO2, Er,Cr:YSGG, 
Nd:YAG, KTP, Er:YAG). Pharmacological treatment 
possibilities include carotenoids, retinoids, topical an-
tioxidants and bleomycin4. Lasers are widely used in 
medicine and dentistry owing to their beneficial ef-
fects such as coagulation properties (less perioperative 
and postoperative bleeding), and less edema and pain 
after surgical procedure. Furthermore, the use of abla-
tive lasers results in good and fast healing process, a 
low level of patient discomfort during and after inter-
vention, and rapid disappearance of postsurgical symp-
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toms. The main objective in the treatment of oral leu-
koplakia is to remove potentially neoplastic cells in an 
attempt to prevent malignant transformation5. In the 
searched literature on Pubmed (May, 2015), there are 
publications on the effectiveness of CO2 lasers in the 
treatment of oral leukoplakia. Nevertheless, to the best 
of our knowledge, there are only two reports on the use 
of Er:YAG lasers in the treatment of oral leukopla-
kia6,7. Er:YAG laser will ablate tissue efficiently at a 
relatively low fluence of about 0.5 to 1.5 J/cm2 with 
minimal residual thermal damage8. Er:YAG laser is ef-
fective for superficial ablation, although deeper vapor-
ization has been hampered by ineffective hemostasis8. 
Therefore, Er:YAG lasers are useful for lesions that are 
located in the superficial areas where a certain degree 
of hemostasis can be achieved. Using repetitive pulses 
at the same site can help in achieving significant de-
gree of ablation while one pulse followed quickly by 
another will vaporize tissue before the area starts to 
bleed. Er:YAG laser is a very valuable tool in surgery as 
it has the coefficient degree of absorption by water ten 
times that of the CO2 laser9,10. Er:YAG laser minimal-
ly damages epithelial tissues, results in low inflamma-
tory reaction, has quicker healing process and lower 
risk of scarring11. The latest laser technology allows for 
extremely precise ablation or excision of lesions using 
a digitally controlled dental laser handpiece12. This 
provides a possibility to guide the Er:YAG laser beam 
automatically in the required shape and dimension 
with precise coverage of relatively large areas13.
Various studies have evaluated therapeutic effec-
tiveness of vitamin A derivatives in the treatment of 
oral leukoplakia, however, with inconsistent results. 
Most of the relatively scarce studies on topical use of 
isotretionin in various percentages report on improve-
ment in patients with oral leukoplakia14-16.
Therefore, the aim of this preliminary study was to 
evaluate the effectiveness of ablative Er:YAG laser in 
comparison to the 1% topical isotretionin therapy in 
the treatment of oral leukoplakia. Another aim of the 
study was to evaluate the quality of life and postopera-
tive pain after laser treatment.
Subjects and Methods
The study was approved by the Ethics Committee, 
School of Dental Medicine, University of Zagreb. Ev-
ery participant signed informed consent according to 
Helsinki II. The study was performed at the Depart-
ment of Oral Medicine and Department of Oral Sur-
gery, School of Dental Medicine in Zagreb, Croatia. 
There were 27 patients (17 women and 10 men), age 
range 24-73 years, with 27 leukoplakic lesions involved 
in this study. Detailed medical history was taken and 
clinical examination performed in all patients. All 27 
leukoplakic lesions were histopathologically confirmed 
as oral leukoplakia prior to any treatment. Lesions 
were measured (in millimeters), exact localization of 
the leukoplakic lesions was recorded, as well as data 
regarding tobacco and alcohol consumption. As the 
first option, in every participant leukoplakia was treat-
ed with 1% topical isotretinoin in orabase (Roaccu-
tane®, Hoffmann-La Roche, Basel, Switzerland), and 
Orabase® (ConvaTec, Deeside, United Kingdom), 
mixed in the same amounts, which was applied three 
times a day during the period of one year. Then the le-
sions were re-measured and there were no differences 
in the lesion size, except for one patient in whom the 
lesion was smaller but still present. Then, an Er:YAG 
laser (LightWalker AT, Fotona, Slovenia) with a non-
contact X-Runner digitally controlled hand piece was 
used on the same group of participants. This digitally 
controlled hand piece for Er:YAG laser, with integrat-
ed scanning mechanism within the ergonomic box lies 
on the operator’s hand. The treatment area and size 
was defined on the device by the operator according to 
the shape and size of treated lesion, and the laser beam 
was automatically guided across the treated tissue sur-
face. There were three primary treatment shapes (cir-
cular, rectangular and hexagonal) that could be selected 
with the X-Runner hand piece, and these could be set 
according to the size of treatment area (width and 
length of the rectangle, or diameter in case of circle 
and hexagon), up to 6 mm. After applying local anes-
thetic (Ubistesin 2%, 3M ESPE, Seefeld, Germany), 
up to 1 mL, depending on the size and localization of 
the lesion, laser parameters were selected. Er:YAG la-
ser was used in a non-contact mode and settings were 
as follows: pulse mode was Quantum Square Pulse 
(QSP), pulse energy of 120 mJ and frequency of 20 
Hz. Round, rectangular or hexagonal shape was se-
lected according to the size and shape of the lesion. 
The hand piece was held at a distance of 15 mm from 
the lesion surface and water spray level was set to 10 
mL/min. All hyperkeratotic lesions were removed 
completely by the laser ablation process and the num-
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ber of ablations depended on lesion size. Patients were 
recalled and examined after one, two, four, eight weeks, 
six months and one year after the first ablation. At the 
follow-up, every lesion was re-measured if needed or 
still present and decided whether there was a need to 
repeat laser treatment. The lesions where relapse was 
observed were ablated once more to final removal. 
Postoperative pain was determined by the visual ana-
log scale (VAS), range 0-10, where 0 denotes no pain 
and 10 worst pain. Furthermore, each patient filled in 
the Oral Health Impact Profile (OHIP), which con-
sisted of 14 questions on the impact of laser treatment 
on the quality of their life. The normality of distribu-
tion was tested with Kolmogorov-Smirnov test. Since 
data were normally distributed, χ2-test and Pearson’s 
correlation were used on further analysis. Differences 
between male and female subjects and differences 
based on recurrence rate were calculated by χ2-test for 
categorical variables and Student’s t-test for continu-
ous variables. The level of statistical significance was 
set at p<0.05. The study was initiated in June 2013 and 
completed in November 2014.
Results
There were no differences in the size of leukoplakic 
lesions before and after topical isotretinoin treatment, 
except for one patient. There were significant differ-
ences between men and women in laser group accord-
ing to localization of leukoplakic lesions, number of 
laser sessions and VAS (p<0.05) (Tables 1 and 2). All 
leukoplakic lesions found sublingually were observed 
in women. Men had more laser sessions when com-
pared to women (p=0.036). Women tended to have 
higher VAS scores in comparison to men (p=0.008). 
Recurrence rate of leukoplakic lesions was 74.1% after 
first ablation treatment (Table 2). Follow-up of the le-
sions was performed after one, two, four, eight weeks, 
six months and one year. Some of the patients had few 
ablations per visit. However, at the recall visits after six 
months and one year, there was no recurrence of leu-
koplakic lesions ablated using Er:YAG laser. The 
OHIP total score was 9.6±9.8, without any statisti-
cally significant differences between men and women 
in this group (p>0.05) (Table 2).
Discussion
There are scarce data on the effectiveness of Er:YAG 
lasers in the treatment of oral leukoplakia6,7. Meister et 
al.6 report a case of Er:YAG use for the treatment of 
leukoplakia of buccal mucosa. Schwarz et al.7 treated ten 
patients with 16 leukoplakic lesions with Er:YAG or 
CO2 lasers. The aim of this preliminary study was to 
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Dragana Gabrić et al. Evaluation of Er:YAG laser in treatment of leukoplakia
618 Acta Clin Croat, Vol. 58, No. 4, 2019
evaluate the effectiveness of Er:YAG laser with a non-
contact X-Runner digitally controlled hand piece in the 
treatment of oral leukoplakia. The great advantage of 
such a hand piece is the ability to treat relatively large 
areas of different shapes extremely precisely and uni-
formly. The laser beam in this case is automatically guid-
ed, which allows the use of higher repetitions and faster 
finishing of the procedure. Furthermore, the QSP mode 
was used in the present study. QSP is a specific pulse 
mode in which a longer laser pulse is divided (quan-
tized) into several super-short pulses that follow each 
other at an optimally fast rate17. This enables the QSP 
mode to deliver super-short, low-energy pulses with ef-
ficiency of long-duration, higher energy laser pulses 
without sacrificing the efficiency and precision that is 
provided by super-short duration pulses17. Regarding 
removal of soft tissues, the ablation is very precise and 
heals even faster than with longer pulse mode due to the 
minimally invasive delivery of short, low energy pulses 
of high frequency12.
Since there were no differences in the size of leuko-
plakic lesions before and after topical isotretinoin 
treatment, except for one patient, only results recorded 
in the laser group were analyzed. The results of this 
study showed gender differences according to localiza-
tion of leukoplakic lesions, number of laser sessions 
and VAS score in the laser group of patients. All sub-
lingual lesions were observed in women. Study results 
revealed that sublingual leukoplakia recurred less fre-
quently as compared to leukoplakia on buccal mucosa 
and tongue. It seems that sublingual area is the one 
without recurrences probably owing to higher vascu-
larization of the area in comparison to other treated 
areas. Furthermore, it may be that tongue protects sub-
lingual area from mechanical injuries. The last but not 
the least, saliva secreted from the submandibular and 
sublingual glands has a protective role, especially as it 
contains mucins, unlike parotid saliva. Significantly 
more laser sessions recorded in men probably reflect 
the finding that men tended to have lesions on buccal 
mucosa, unlike women who tended to have lesions 
sublingually. It might be that buccal mucosa is more 
prone to mechanical trauma due to mastication and 
therefore recurrences in this area are more frequent. 
Contrary to our results, Jerjes et al.18 report that recur-
rence of leukoplakia does not correlate with its local-
ization.
According to the results of this study, the recur-
rence rate of leukoplakic lesions was 74.1% in general. 
However, at the recall visits after six months and one 
year, there was no recurrence of any leukoplakic lesion. 
In the present study, when the lesions were removed 
with laser for the first time, ablation of the epithelial 
tissue was performed with little or no capillary bleed-
ing from the connective tissue. On a subsequent visit, 
if recurrence of the lesion was observed, ablation was 
performed to a greater depth with capillary bleeding 
and there was no recurrence at the recall after six 
months and one year. It is important to ascertain the 
borders of the lesion, including its margin and depth. 
Table 2. Data on laser parameters, number of ablations, recurrence rate, VAS and OHIP
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VAS (mean ± SD) 2±3 0.008* 0.200
OHIP 9±9 0.493 0.283
VAS = visual analog scale; OHIP = Oral Health Impact Profile; *statistically significant (p<0.05)
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If the ablation depth is not sufficient, the remaining 
basal cell layer may consist of highly proliferating cells, 
which may cause recurrence of leukoplakia17. Probably 
these proliferating cells, which remained after the first 
laser ablation in this study, caused recurrence of leuko-
plakia and were removed in the next session when 
deeper ablation was performed to ensure complete re-
moval of the lesion. Other studies report different data 
regarding recurrence of leukoplakia. The results report-
ed by Schwartz et al.7 revealed that Er:YAG laser ex-
hibited complete elimination of three leukoplakic le-
sions and partial elimination of five lesions within the 
testing period. Thomson and Wylie3 report on the 24% 
recurrence rate after laser surgery, similar to the results 
reported by Ishii et al.17, who found recurrence of leu-
koplakia in 29% of cases. Brouns et al.19 report on 8% 
and Jerjes et al.18 on 19.5% rate of leukoplakia recur-
rence after laser ablation. The results of our study are in 
concordance with the results of Meister et al.6, which 
showed complete disappearance of oral leukoplakia by 
use of Er:YAG laser.
Differences between the results of this study and 
those from other studies found in the literature could 
be due to different laser devices, hand pieces and pa-
rameters chosen, as well as to differences in the meth-
odology employed in particular studies.
Scardina et al.14 compared the efficacy of 0.18% 
topical isotretinoin with 0.05% topical isotretinoin for 
the treatment of oral leukoplakia in 40 patients. The 
drug was applied twice a day for three consecutive 
months and there was significant reduction in lesions 
(85%), with no documented topical or systemic ad-
verse reactions at 0.18% concentration. Tetè et al.15 
evaluated the role of bcl-2 protein and apoptotic bod-
ies in topical treatment of oral leukoplakia with 0.1% 
isotretinoin gel (applied three times a day) in 15 pa-
tients. In 14 patients, there was marked improvement 
of the dimension and clinical aspect of the lesions (to-
tal remission in three and improvement of the size and 
clinical appearance of the lesion by 50% or more in 11 
cases). Piattelli et al.16 treated ten patients with oral 
leukoplakia with 0.1% isotretinoin gel (three topical 
applications) and the lesions subsided completely in 
two patients, whereas 50% improvement was recorded 
in eight patients. However, the results of our study 
showed that there was no improvement in the size of 
leukoplakic lesions treated with topical isotretionin 
even in higher concentration during the one-year pe-
riod. Therefore, we do not suggest topical treatment in 
patients with oral leukoplakia.
Although Er:YAG laser revealed successful results 
in the treatment of oral leukoplakia, patients have to 
be advised that close follow-up (every six months) is 
advisable as there is the risk of recurrence of the previ-
ously ablated lesions, as well as development of new 
lesions over time.
Conclusion
We conclude that the Er:YAG laser with a non-
contact X-Runner digitally controlled hand piece may 
be a successful treatment option for leukoplakia as no 
recurrence of lesions was observed at one-year follow-
up. On the contrary, 1% topical isotretinoin treatment 
was unsuccessful in the same group of patients.
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Sažetak
EVALUACIJA INOVATIVNO DIGITALNO KONTROLIRANOG Er:YAG LASERA  
U LIJEČENJU LEUKOPLAKIJE – PROBNO ISTRAŽIVANJE
D. Gabrić, V. Brailo, A. Ivek, K. Krpan, N. Matulić, D.V. Vrdoljak, A. Baraba i V. Vučićević Boras
Posljednjih godina postoji veliko zanimanje za upotrebu lasera u liječenju oralne leukoplakije, ali su podatci o upotrebi 
Er:YAG lasera malobrojni. Cilj ovoga istraživanja bio je usporediti učinak Er:YAG lasera i 1%-tnog topikalnog izotretinoina 
u liječenju 27 bolesnika s oralnom leukoplakijom. Er:YAG laser (LightWalker AT, Fotona, Slovenia) je korišten u 27 bole-
snika s 27 leukoplakičnih lezija. Poslijeoperacijska bol je određena uz pomoć vizualne analogne ljestvice (visual analog scale, 
VAS), a utjecaj na kvalitetu života mjeren je pomoću upitnika OHIP-14 (hrvatska verzija). Kontrolna skupina se sastojala od 
istih 27 bolesnika koji su prije toga liječeni 1%-tnim topikalnim izotretioninom tri puta na dan tijekom tri mjeseca. Nije bilo 
poboljšanja u veličini lezija leukoplakije nakon topikalno primijenjenog izotretinoina. Utvrđene su značajne razlike između 
muškaraca i žena s obzirom na lokalizaciju leukoplakije, broj laserskih zahvata i rezultata VAS (p<0,05). Šest mjeseci i  godinu 
dana od laserskog zahvata nije bilo recidiva oralne leukoplakije. Er:YAG laser je uspješna terapija u liječenju oralne leukopla-
kije. Topikalna primjena izotretionina nije uspješna u liječenju oralne leukoplakije.
Ključne riječi: Leukoplakija, oralna; Laseri, kruti; Izotretinoin; Ablacija, tehnike
